| Location: Brisbane, AU
Anne-Marie is a Co-Founder of OneVentures and serves as a Director on the OneVentures Board, Responsible Manager and member of the Risk Committee. She is a voting member of the Investment Committees for Funds I, II and III.
She is a Director for OneVentures portfolio company Madorra and previously chaired the CharmHealth board, leading its acquisition by the Citadel Group in 2017 (ASX: CGL).
With 25 years in product development and commercialisation and 15 years in funds management, Anne-Marie has held significant leadership roles, including CEO of i.lab Incubator and General Manager Operations at UniQuest. She is deeply engaged with industry, universities and government, fostering scientific innovation and commercial success.
A champion for diversity, she co-founded Women in Biotechnology (which later merged into Women in Technology), served on the board of Springboard Enterprises and mentors entrepreneurs, scientists and emerging leaders in venture capital.
Anne-Marie is a Director for InterFinancial, ASX-listed PPK Group (ASX: PPK) and UniQuest. She chairs the Project Investment Committee and is a member of the Industry Steering Committee for the University of Queensland-led Trailblazer Food and Beverage Accelerator.
Holding a Bachelor of Science (Hons), an MBA and PS146 accreditation, she is a member of the Australian Institute of Company Directors (MAICD), a Registered Technology Transfer Professional (RTTP) and a Fellow of the Australian Academy of Technological Sciences and Engineering (FTSE).
| BSc(Hons), MBA, GAICD
| Healthcare
| Location: Melbourne, AU
Jeannie is a Venture Partner at OneVentures, supporting healthcare portfolio company operations and strategic initiatives.
She serves on the board of ImmVirX (deal lead), BiVACOR Pty Ltd, BiVACOR Australia and Hatchtech, and has previously held board roles with BiVACOR Inc (as Chair and Director).
A biopharmaceutical and medical device leader with 20+ years of global experience, Jeannie has held senior executive and advisory roles in Australia and the US. Her expertise includes business development, strategic partnerships, and operational leadership across research, clinical trials, and commercial management.
In the US, she led global business development, licensing medical device technologies to major pharmaceutical companies and securing milestone and royalty payments. Her career includes roles with organisations such as Bristol-Myers Squibb, Mayne Pharma, CSL, and Enable Injections.
Jeannie holds a PhD and a Bachelor of Science (Hons) in Immunology from Monash University and a Diploma of Marketing from the Melbourne Business School. She currently serves as a Non-Executive Director for ASX-NASDAQ listed Immuron and ASX-listed Argenica.
| BSc(Hons), PhD
| Healthcare
| Location: Sydney, AU
John is a Venture Partner at OneVentures supporting the Healthcare team and portfolio companies with strategic guidance and operational expertise.
He has over 20 years of global experience in life sciences spanning operational leadership, venture capital and investment banking.
Previously, John was CFO of Elastagen, an Australian medical device company, where he led fundraising. He also played a key role in the international expansion of the company’s clinical studies in the UK and in the company’s acquisition by Allergan. Elastagen was recognised as the Australian Investment Council’s Best Venture Capital Investment of 2018. Post-acquisition he oversaw the integration of Elastagen’s clinical programs as Director of R&D and later as a consultant.
Prior to his tenure at Elastagen, John spent eight years at Nomura Phase4 Ventures in London investing in early to mid-stage life science companies across the US and Europe. He began his career at Morgan Stanley advising healthcare multinationals on capital raising, divestitures and acquisitions.
John holds a PhD and a BSc (Hons) in Biochemistry from Heriot-Watt University, completing the first year of his PhD at Dundee University. He is a recipient of the Watt Club Medal.
| BSc(Hons), PhD
| Healthcare
| Location: United States
Dan Baker received his B.A. in Biology from Gettysburg College and his medical degree from the University of Pennsylvania. He completed his medical residency at Hershey Medical Center and fellowship in Rheumatology at the University of Pennsylvania, followed by a research fellowship in Rheumatology at Mass General Hospital. He continued on the faculty of the University of Pennsylvania for 18 years before joining Janssen/Centocor in 2000.
As Vice President Immunology R&D at Janssen, his responsibilities included the clinical development of Remicade, SIMPONI and STELARA as well as other programs in rheumatology, and dermatology. As Disease Area Stronghold Leader he was responsible for Phase II & III clinical development plans for rheumatology products was responsible for the overall strategy on portfolio in rheumatology/immunology.
He has authored multiple publications in the field of immunology and has served a co-Lead of RTCure which is an academic/industry collaboration that is sponsored by IMI2 and is searching for tolerogenic therapies for rheumatoid arthritis.
After his retirement from Janssen in 2019 he has been active in continuing to be involved in bringing therapies to patients by providing scientific advice to drug development organisations. He has taken on the role of CEO of Kira Biotech which is an emerging Australian biotech company targeting treatment of immune system disorders with novel immunomodulatory drugs.
| BSc (Biology), MD (Rheumatology)
| Healthcare
| Location: United States
Jim is a Venture Partner at OneVentures, serving on the investment committee of Healthcare Fund III, a board member of BiVACOR, and an advisor to the healthcare team.
An experienced venture capitalist and former healthcare investment banker, Jim brings expertise in the biopharmaceuticals, medical devices, and diagnostics sectors of life sciences.
He previously served as a Managing Director and member of the Investment Committee at MPM Capital, a US$2.6 billion global venture fund focused on early-stage life sciences. He has 18 years of experience in healthcare investment banking, advising emerging growth companies on financings and strategic transactions as a Managing Director at Deutsche Bank and Thomas Weisel Partners.
Jim has served on the boards of DICE Pharmaceuticals (sold to Eli Lilly for $2.4 billion in 2023), Semma Pharmaceuticals (sold to Vertex for $950 million in 2019), and True North Therapeutics (sold to Bioverativ for $825 million in 2017).
He was appointed a Fellow at the Distinguished Career Institute at Stanford for 2017–2018. He holds an MBA, JD (Harvard).
| MBA, JD (Harvard)
| Growth Equity
| Location: Sydney, AU
Amrita is a Growth Equity Venture Partner at OneVentures, supporting our technology portfolio companies with her operations and strategy expertise.
An experienced C-suite executive and Non-Executive Director, Amrita brings extensive expertise in strategy, operations, manufacturing, pricing, sales, and marketing across technology and healthtech companies.
Her leadership roles include serving as Co-CEO of SomnoMed (ASX: SOM) and as Chief Operating and Marketing Officer at eBay Australia.
Amrita is a Non-Executive Director at Audinate (ASX: AD8) and Genea, and has worked as a management consultant.
She holds an MBA from Harvard Business School and a Bachelor of Engineering (Biomedical).
| BE(Hons), MBA
| Growth Equity
| Location: United States
Mark is a Growth Equity Venture Partner at OneVentures, where he supports portfolio companies with operational improvements and US market entry strategies.
In addition, he advises our Fund VII Investment Committee, bringing extensive expertise in scaling technology companies and driving cross-border growth.
Mark is a seasoned C-suite executive with key leadership experience, including his current role as CEO of LCvista (PE-backed), and prior roles as COO of Cordance (PE-backed), and US Country Manager for Message Media, where he played a pivotal role in the company’s $1.8B exit.
Previously, he was a Principal in Portfolio Operations at Technology Crossover Ventures (TCV), providing strategic guidance to high-growth technology companies.
| MBA
| Growth Equity
| Location: United States
Jim is a Growth Equity Venture Partner at OneVentures, where he helps technology portfolio companies develop and implement their go-to-market strategies and growth initiatives.
He is a consulting advisor to portfolio companies Phocas, Shippit, and Buildkite, working closely with their CEOs and executive teams to scale operations and achieve strategic goals.
A seasoned C-suite executive, Jim has held leadership roles including GM at Fortify (acquired by HP), VP of Global Field Operations at AlienVault (acquired by AT&T), COO and CEO at CrownPeak (acquired by K1), Executive VP of Global Field Operations at Illumio, and CRO at Banyan Security (acquired by SonicWall).
Earlier in his career, he served as a Managing Director at KPMG and later Bearing Point’s High Tech Practice.
